Research use only. Everything below is written for qualified researchers. Semaglutide and tirzepatide are approved medicines in some countries, but the material discussed here is sold strictly as a research compound and is not for human use.
Three names have taken over metabolic research in the space of a few years: semaglutide, tirzepatide, and, more recently, retatrutide. It is tempting to file all three under “GLP-1 drugs” and move on, but that label hides differences that matter once you are choosing which compound to actually work with. The tirzepatide vs semaglutide question comes up more than any other, so we will start there, then bring retatrutide, the newest and most aggressive of the three, into the picture.
Here is the one-sentence version before we get into detail: semaglutide engages one receptor, tirzepatide engages two, and retatrutide engages three. More targets has, so far, meant more weight lost in trials. It is not quite that clean a story, though, and the caveats are where the interesting research questions live.
Tirzepatide vs semaglutide: the short version
In a straight tirzepatide vs semaglutide comparison, the starting point is simply how many receptors each one engages. Semaglutide, better known by the brand names Ozempic and Wegovy, is a GLP-1 receptor agonist and nothing more. Tirzepatide (Mounjaro, Zepbound) keeps the GLP-1 activity and adds a second incretin receptor, GIP. That extra target is the whole story of why the two behave differently. Across Eli Lilly’s SURPASS and SURMOUNT trials, tirzepatide produced larger reductions in both body weight and HbA1c than semaglutide managed in its own STEP program.
What is still debated is why. Some groups argue the GIP arm does real independent work; others think it mostly sharpens the GLP-1 response. For a researcher, that open question is half the appeal, because it is exactly the kind of thing a well-designed in-vitro comparison can probe. The outcome data itself, however, is not ambiguous: at the top doses, tirzepatide went further.
One receptor, two, or three
The three compounds are best understood by what they switch on. GLP-1 signalling drives insulin release, slows gastric emptying, and dampens appetite through the brain. GIP adds effects on insulin sensitivity and fat tissue. Glucagon, the receptor retatrutide brings to the table, is the surprising one: on its own you might expect it to raise blood sugar, but paired with the incretin receptors it appears to lift energy expenditure, which is a different lever entirely.
So the progression from semaglutide to tirzepatide to retatrutide is not just “more of the same.” Each step adds a mechanistically distinct pathway, and that is why the three are worth studying alongside each other rather than treating the newest as simply a better version of the last.
What the weight-loss numbers actually say
The cleanest way to compare is by trial outcomes, with one important caveat: these figures come from separate studies with different participants and endpoints, so treat the table as a guide to scale, not a true head-to-head.
| Compound | Brand names | Receptors | Peak average weight loss | Half-life |
|---|---|---|---|---|
| Semaglutide | Ozempic, Wegovy | GLP-1 | ~15% (STEP-1, 68 weeks) | ~7 days |
| Tirzepatide | Mounjaro, Zepbound | GIP + GLP-1 | ~21% (SURMOUNT-1, 72 weeks) | ~5 days |
| Retatrutide | Investigational | GIP + GLP-1 + glucagon | up to ~30% (Phase 3 TRIUMPH) | ~6 days |
That, in a single column, is the tirzepatide vs semaglutide gap that kicked off the whole conversation. Read down that middle column and the pattern is hard to miss: each added receptor lines up with a larger effect on weight. Correlation is not mechanism, and cross-trial comparisons are famously unreliable, but the trend has held up well enough that it now shapes how the whole field thinks about incretin design.
Where retatrutide changes the math
Retatrutide is the one still in development. It has no Health Canada or FDA approval and exists, for now, only as an investigational compound and a research chemical. What makes it interesting is that glucagon receptor: in the Phase 3 TRIUMPH program, the top dose reached weight reductions in the region of 30 percent, territory that used to belong to surgery rather than injections.
If your work is comparative, the tirzepatide vs semaglutide pairing is only the beginning, and retatrutide is the obvious third data point. We cover it in depth in our Retatrutide research guide, including the trial readouts and how the triple-agonist mechanism is thought to work. For a broader primer on tirzepatide specifically, the Tirzepatide guide goes further than we can here.
Sourcing research-grade material in Canada
Whichever compound you land on, the practical problem is the same: for reproducible results, the certificate of analysis matters more than the label on the vial. Purity varies wildly between suppliers in an unregulated market, and a batch that is 92 percent pure will quietly wreck a protocol you spent weeks designing.
The short checklist worth applying to any of the three is an independent COA showing 99 percent or higher purity for the specific lot, domestic Canadian shipping so the material is not sitting in customs, and clear batch-level traceability. For tirzepatide, most Canadian labs we hear from source third-party-tested tirzepatide from Anglo Peptides, where each batch ships with its own Janoshik-verified certificate. Before reconstituting anything, it is worth running the numbers through Anglo Peptides’ peptide calculator so your concentrations are right the first time.
Questions researchers ask
Tirzepatide vs semaglutide: which is actually stronger?
In trial data, yes, at comparable top doses tirzepatide produced larger weight and HbA1c reductions. The two were not tested identically, so the gap is directional rather than exact.
Is tirzepatide the same as Ozempic?
No. Ozempic is a brand of semaglutide, a single GLP-1 agonist. Tirzepatide (Mounjaro, Zepbound) is a dual GIP/GLP-1 agonist and a different molecule.
How does retatrutide differ from both?
It adds a third receptor, glucagon, on top of GIP and GLP-1. That extra pathway is linked to higher energy expenditure and, in Phase 3 trials, the largest weight reductions of the three.
Which is best for research use?
That depends on the question. Semaglutide is the reference GLP-1 agonist, tirzepatide is the benchmark dual agonist, and retatrutide is the frontier triple agonist. Comparative studies increasingly use all three.
Disclaimer: This article is for educational and research reference only. The compounds discussed are supplied strictly for in-vitro laboratory research and are not for human or animal consumption. Nothing here is medical advice.